SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) was featured in a BioMedWire editorial that examines the rapid expansion of the GLP-1 market and highlights the company's development of GEP-44, a patented triple agonist peptide licensed from Syracuse University. The editorial notes that GEP-44 is designed to target GLP-1 and peptide YY receptors Y1 and Y2, positioning SureNano as an emerging microcap participant seeking to address limitations of first-generation GLP-1 therapies, including efficacy, tolerability and delivery flexibility.
The coverage places SureNano alongside established and emerging metabolic disease companies such as Merck & Co. (NYSE: MRK), AbbVie (NYSE: ABBV), Viking Therapeutics (NASDAQ: VKTX) and Altimmune (NASDAQ: ALT), underscoring accelerating momentum across the obesity, diabetes and cardiometabolic treatment landscape. BioMedWire notes SureNano's broader platform strategy, including evaluation of oral, sublingual and intranasal delivery approaches, as well as early-stage opportunities involving formulation and delivery technologies that could expand the company's long-term therapeutic scope.
SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets. The company has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery. The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano(TM) surfactant, which provides the base for high performance nanoemulsions.
The full press release can be viewed at https://ibn.fm/2NGrw. For more information about SureNano Science Ltd., visit the company's newsroom at https://ibn.fm/SURNF.
This editorial coverage highlights the growing interest in next-generation GLP-1 therapies and the potential for companies like SureNano to contribute to the treatment of obesity and metabolic diseases. The GLP-1 market has seen significant growth, and SureNano's triple agonist approach may offer advantages over existing therapies, particularly in terms of tolerability and delivery options.
